Senescent cells, senolytics and tissue repair: the devil may be in the dosing.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37118118.
- Also identified by DOI 10.1038/s43587-023-00365-6 and PMC identifier 10148948.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There is tremendous interest in the development of drugs that target senescent cells (‘senolytic’ drugs) to treat a range of age-related morbidities. However, studies in mice that demonstrate impaired tissue repair following clearance of senescent cells raise questions about the potential risks of senolytic therapies. Closer examination of the available studies reveals the hopeful possibility of a ‘therapeutic window’ in which these risks can be minimized.
Medical subject headings
- Senotherapeutics
- Cellular Senescence